Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anitocabtagene autoleucel (anito-cel) which is being prepared for a filing and potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results